Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Recommendation of “Hold” by Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $22.50.

A number of equities analysts have weighed in on DCTH shares. Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. BTIG Research decreased their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Evercore set a $27.00 price target on Delcath Systems in a report on Thursday, February 26th. Finally, Zacks Research cut Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th.

Delcath Systems Stock Up 6.9%

NASDAQ DCTH opened at $11.69 on Wednesday. The stock has a market cap of $403.54 million, a PE ratio of 1,169.00 and a beta of 0.54. Delcath Systems has a fifty-two week low of $8.12 and a fifty-two week high of $16.56. The business has a 50 day moving average price of $10.68 and a two-hundred day moving average price of $10.08.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The firm had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. Sell-side analysts anticipate that Delcath Systems will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently made changes to their positions in DCTH. Nantahala Capital Management LLC purchased a new position in shares of Delcath Systems during the 3rd quarter valued at approximately $7,164,000. Marshall Wace LLP purchased a new position in shares of Delcath Systems during the 2nd quarter valued at approximately $6,572,000. Divisadero Street Capital Management LP purchased a new position in shares of Delcath Systems during the 3rd quarter valued at approximately $5,119,000. Rosalind Advisors Inc. boosted its stake in shares of Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after buying an additional 400,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Delcath Systems by 116.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after buying an additional 315,583 shares during the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.